Phase I Testing Begins on Second Compound Developed from AMRI (AMRI), Bristol-Myers (BMY) Collaboration; AMRI to Receive $4M Milestone Payment
More News related to AMRI
- Albany Molecular Research (AMRI) Posts Q3 Loss of $0.02, Tops by 2c; Guides
- AMRI Announces Third Quarter 2009 Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
- AMRI to Present at the Oppenheimer 20th Annual Healthcare Conference
More News related to BMY
- New Data on Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 51st Annual Meeting of the American Society of Hematology
- Mead Johnson Loses $13.5 Million Lawsuit to PBM Products
- Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
- New Initiative: "Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
- Notable 52-Week High's and Low's: BMY, JCG, PBR, SLW, GOOG, INCY, NTAP, QADI, GOLD, BONT Higher; SPWRB Low
More News related to Corporate News
- CB Richard Ellis (CBG) Announces that CEO Sale of 162K of Common Made Pursuant to Previous Election
- Dolphin Equity Realized $93M from Gomez Sale to Compuware (CPWR)
- General Motors (MTLQQ)(GM) Announces Several Management Changes
- Quigley Corp. (QGLY) CEO Announces Focus on OTC/Personal Care Marketplace; IDs Possbile Pharma Products for Further Investment
- KIT digital (KITD) Reports on Nenet and FeedRoom Integration; Updates on FY09 Guidance
AMRI (NASDAQ: AMRI) announced today that Bristol-Myers Squibb Company (NYSE: BMY) has submitted a Clinical Trial Application to the Medical Products Agency in Sweden for approval to initiate Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. Upon approval of the CTA by the MPA, Bristol-Myers Squibb may begin Phase I testing in Sweden.
AMRI will receive a $4 million milestone payment from Bristol-Myers Squibb as a result of the submission of this CTA per the collaborative agreement between the two companies. This is the second AMRI compound from this collaboration to be selected by Bristol-Myers Squibb for Phase I testing. Bristol-Myers Squibb initiated a Phase I study on a separate AMRI compound in Canada in 2008.
This is the fourth milestone payment in the on-going research collaboration to develop improved treatments for depression and diseases of the central nervous system bringing the total milestone and licensing fees earned to date to $17.5 million. The two companies will continue to evaluate additional compounds.
Under the collaborative agreement, AMRI is potentially eligible to receive up to $66 million per compound in development and regulatory milestone payments for the first two compounds, and additional payments of up to $22 million per compound on subsequent compounds. In addition, AMRI will receive royalties on worldwide sales of commercialized compounds.
Related Categories
Corporate NewsStocks Mentioned
+0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
